WO2012053856A3 - Respiratory syncytial virus vaccine composition and method for preparing same - Google Patents
Respiratory syncytial virus vaccine composition and method for preparing same Download PDFInfo
- Publication number
- WO2012053856A3 WO2012053856A3 PCT/KR2011/007882 KR2011007882W WO2012053856A3 WO 2012053856 A3 WO2012053856 A3 WO 2012053856A3 KR 2011007882 W KR2011007882 W KR 2011007882W WO 2012053856 A3 WO2012053856 A3 WO 2012053856A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rsv
- vaccine
- preventing
- protein
- respiratory diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a vaccine composition for preventing and treating respiratory diseases induced by respiratory syncytial virus (RSV), and a method for preparing same. More specifically, the present invention relates to a procaryotic cell expression vector for preparing a vaccine for treating or preventing respiratory diseases induced by RSV, the procaryotic cell expression vector comprising a nucleic acid sequence for coding a whole or a part of a peptide fragment having an amino acid 120th to 230th from an N-terminal of RSV G protein; a procaryotic cell transformant for preparing the vaccine for preventing and treating respiratory diseases induced by RSV, the procaryotic transformant being transformed by the expression vector; a method for preparing a peptide fragment of RSV G protein for the vaccine for preventing and treating respiratory diseases induced by RSV, the method using the procaryotic transformant; a vaccine composition for preventing and treating respiratory diseases induced by RSV, the vaccine composition comprising a whole or a part of the peptide fragment having an amino acid 120th to 230th from the N-terminal of the RSV G protein; and a method for preventing or treating respiratory diseases due to RSV infection, the method comprising a step for administering the vaccine composition to a subject. The vaccine comprising procaryotic cell expression RSV G protein fragment according to the present invention induces very high blood serum IgG and respiratory mucosa IgA from just two immunizations, and displays effective defense against RSV replication without showing eosinophilic immunopathological effect due to the vaccine at the time of an RSV infection. Also, the present invention has very high economic efficiency as the vaccine uses a protein purified from bacteria, and resolves the problem of stability that can result from a virus vaccine by using a purified protein fragment as the vaccine having antigenicity, thereby making the present invention advantageous considering that the main subjects of RSV vaccine immunization are newborn and infants. Also, the present invention shows sufficient immunity even from sublingual administration, which has superior stability, and therefore, has an effect of increasing the stability of vaccine immunization.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0102976 | 2010-10-21 | ||
KR20100102976 | 2010-10-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012053856A2 WO2012053856A2 (en) | 2012-04-26 |
WO2012053856A3 true WO2012053856A3 (en) | 2012-08-02 |
Family
ID=45975759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/007882 WO2012053856A2 (en) | 2010-10-21 | 2011-10-21 | Respiratory syncytial virus vaccine composition and method for preparing same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101366702B1 (en) |
WO (1) | WO2012053856A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101366702B1 (en) | 2010-10-21 | 2014-02-28 | 이화여자대학교 산학협력단 | Vaccine composition for respiratory syncytial virus and manufacturing method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117070562B (en) * | 2023-08-16 | 2024-03-26 | 北京华诺泰生物医药科技有限公司 | Recombinant respiratory syncytial virus protein vaccine and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040071678A (en) * | 2001-09-28 | 2004-08-12 | 유니버시티 오브 사우스 플로리다 | Rsv gene expression vaccine |
KR20090031053A (en) * | 2007-09-21 | 2009-03-25 | 이화여자대학교 산학협력단 | Respiratory syncytial virus vaccine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001512662A (en) | 1997-07-18 | 2001-08-28 | コノート ラボラトリーズ リミテッド | Nucleic acid vaccine encoding G protein of respiratory syncytial virus |
KR101366702B1 (en) * | 2010-10-21 | 2014-02-28 | 이화여자대학교 산학협력단 | Vaccine composition for respiratory syncytial virus and manufacturing method thereof |
-
2011
- 2011-10-21 KR KR1020110107994A patent/KR101366702B1/en active IP Right Grant
- 2011-10-21 WO PCT/KR2011/007882 patent/WO2012053856A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040071678A (en) * | 2001-09-28 | 2004-08-12 | 유니버시티 오브 사우스 플로리다 | Rsv gene expression vaccine |
KR20090031053A (en) * | 2007-09-21 | 2009-03-25 | 이화여자대학교 산학협력단 | Respiratory syncytial virus vaccine |
Non-Patent Citations (2)
Title |
---|
JAE-RANG YU ET AL.: "Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection", J. VIROL., vol. 82, 2008, pages 2350 - 2357 * |
YAN HUANG ET AL.: "A single amino acid substitution in a recombinant G prote in vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV)", VACCINE, vol. 21, no. 19-20, 2003, pages 2500 - 2505 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101366702B1 (en) | 2010-10-21 | 2014-02-28 | 이화여자대학교 산학협력단 | Vaccine composition for respiratory syncytial virus and manufacturing method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101366702B1 (en) | 2014-02-28 |
KR20120047780A (en) | 2012-05-14 |
WO2012053856A2 (en) | 2012-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107847580B (en) | Vaccines against RSV | |
US20190142951A1 (en) | Influenza antigen delivery vectors and constructs | |
Hong et al. | Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection | |
US9060975B2 (en) | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions | |
HRP20160798T1 (en) | Recombinant rsv antigens | |
MX2019006349A (en) | Novel recombinant prefusion rsv f proteins and uses thereof. | |
JP6735269B2 (en) | Influenza virus vaccine and its use | |
IL276210B2 (en) | Mers-cov vaccine | |
RU2016146801A (en) | VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS | |
US20240067681A1 (en) | Subunit vaccine for treatment or prevention of a respiratory tract infection | |
US9963490B2 (en) | Influenza nucleoprotein vaccines | |
US20230310581A1 (en) | A live attenuated measles virus vectored vaccine for sars-cov-2 | |
JP2015500827A5 (en) | ||
JP2013518052A5 (en) | ||
JP2015525794A5 (en) | ||
Tomčíková et al. | Different mechanisms of the protection against influenza A infection mediated by broadly reactive HA2-specific antibodies | |
WO2012053856A3 (en) | Respiratory syncytial virus vaccine composition and method for preparing same | |
WO2011017442A3 (en) | Anti-rsv immunogens and methods of immunization | |
US20240181034A1 (en) | Human metapneumo virus vaccine | |
WO2014185817A3 (en) | Vaccine for the prophylaxis and treatment of rotavirus infection with a fusion protein as active agent (variants) | |
Kim et al. | Mucosal immunization with recombinant adenovirus encoding soluble globular head of hemagglutinin protects mice against lethal influenza virus infection | |
JP7167088B2 (en) | Influenza virus vaccine and its use | |
WO2011109106A3 (en) | Immunogenic compositions against human progastrin peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11834656 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11834656 Country of ref document: EP Kind code of ref document: A2 |